MetaCap

Myriad Genetics Inc. (MYGN)

NASDAQ: MYGNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

5.46-0.08 (-1.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MYGN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$523.74M
EPS (TTM)
-$1.35
Ex-dividend date
Jul 1, 2009
52-week range
2.74 – 8.09
Day range
5.31 – 5.57
Volume / Avg
1.25M / 2.26M
Beta
—

52-week range

$2.74$8.09

MYGN stock today

Myriad Genetics (MYGN) closed at $5.46 on Nov 20, down 1.44% (-$0.08), versus the S&P 500's 3.70% decline. Shares are 32.5% below their 52-week high of $8.09, set on Nov 25, 2025 and 99.3% above the 52-week low of $2.74, in the middle of the past year's range. MYGN is down 11.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.0%.

Myriad Genetics has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Myriad Genetics

Company profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Samraat S. Raha
Headquarters
Salt Lake City, UT
Employees
2,700
IPO year
1995
Website
myriad.com

Financial highlights

Full financials

In fiscal 2025, Myriad Genetics generated $824.5 million in revenue, down 1.6% from fiscal 2024, its first annual decline since 2022. Myriad Genetics reported a net loss of $365.9 million, compared with a loss of $127.3 million a year earlier. Gross margin was 69.9% (flat year over year) and operating margin -47.0%.

Myriad Genetics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$824.50M$837.60M$753.20M$678.40M$690.60M
Growth-1.56%+11.21%+11.03%-1.77%+23.96%
Net income$-365.90M$-127.30M$-263.30M$-112.00M$-27.20M
EPS (diluted)$-3.95$-1.41$-3.18$-1.39$-0.35

Analyst forecast

Forecast

Consensus (9 analysts)

hold

Avg. price target

$5.90+8.06%

  • Strong buy 0
  • Buy 1
  • Hold 6
  • Sell 1
  • Strong sell 1

Target range

Low $3.80High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.13 vs $-0.25
Surprise
+48.00%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$1.75
Ex-dividend date
Jul 1, 2009

MYGN news

All MYGN news

Myriad Genetics peers

Health Care sector
MYGN peer companies
CompanyPrice% ChgMarket capCompare
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs MYGN
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs MYGN
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs MYGN
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs MYGN
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs MYGN
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs MYGN
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs MYGN
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs MYGN

Indexes, lists and sector

Myriad Genetics stock FAQ

What is Myriad Genetics's stock price today?

MYGN last traded at $5.46 as of Nov 20, 4:00 PM EST, down 1.44% on the day. Prices are delayed at least 15 minutes.

Does Myriad Genetics pay a dividend?

Yes. Myriad Genetics pays $0.00 per share annually. The most recent dividend of $1.75 had an ex-dividend date of Jul 1, 2009.

Who is Myriad Genetics's CEO?

Mr. Samraat S. Raha is the chief executive officer of Myriad Genetics Inc., which has about 2,700 employees.

Has MYGN ever split its stock?

Yes. The most recent MYGN stock split was a 2-for-1 split on Mar 26, 2009, one of 2 splits on record.

What is the MYGN 52-week high?

The 52-week high for MYGN is $8.09 and the 52-week low is $2.74. The stock is currently 32.5% below its high.

Compare MYGN